Novartis sells off skin treatment for $420M

Novartis is selling the global rights to skin medicine Elidel to Sweden's Meda for $420 million, boosting Meda's position in dermatology. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.